Sanofi Will Cooperate in China Review After Bribery Report
This article is for subscribers only.
Sanofi, France’s largest drugmaker, will cooperate with a review of its business in China, after a newspaper reported a whistle-blower’s allegations of bribery.
Sanofi is “committed to cooperating with the authorities in any review they undertake regarding these allegations,” it said in a statement dated Aug. 10.